Engflag

Majegra

Quick links to important sections

Majegra

Majegra_EN

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Majegra

Property Description
Active ingredient Sildenafil Citrate (INN: Sildenafil)
Form Oral, Film-coated tablet
Pharmacological class Selective Phosphodiesterase type 5 (PDE5) inhibitor
General purpose Supports normal male sexual function
Origin Synthetic compound

What Kind of Medicine is Majegra?

Majegra is a prescription-only pharmaceutical product, recognized within clinical practice for its defined role in modulating localized blood flow. This medicine is formally identified by its single active component, Sildenafil, which is delivered for oral administration as a film-coated tablet. Majegra functions as a specific commercial identifier for a medicine containing the substance Sildenafil Citrate, which is the citrate salt form utilized for optimal stability. This product is a synthetic compound, reflecting its origin through chemical synthesis, which contrasts it with naturally derived remedies.

Pharmacological Classification and Composition

The active constituent, Sildenafil, is scientifically categorized as a selective Phosphodiesterase type 5 (PDE5) inhibitor. This classification is clinically recognized for targeting the specific enzyme responsible for regulating vascular smooth muscle tone. Sildenafil’s primary function in this class is to modulate localized blood flow by sustaining higher levels of the messenger molecule cGMP. The composition of Majegra involves the Sildenafil Citrate active agent combined with pharmaceutical-grade solid excipients, ensuring the product is a single-ingredient, validated treatment delivered as a convenient oral tablet.

General Purpose and Core Action

The general purpose of Majegra is to support normal male sexual function where optimized blood flow is a critical physiological requirement. This is achieved through the primary action of Sildenafil: the selective inhibition of the PDE5 enzyme. This mechanism leads to smooth muscle relaxation and subsequently enhanced blood flow. The medicine’s function is strictly auxiliary, working only to assist the body’s natural hemodynamic response following the appropriate biological signals, without initiating the process independently.

Regulatory References

  1. MedlinePlus, Sildenafil Classification
  2. NIH/NCBI Sildenafil Overview

What side effects are possible with Majegra?

Possible Side Effects and Safety Information

The official safety documents for Majegra, which contains Sildenafil Citrate, categorize possible adverse reactions based on their reported frequency in clinical use and post-marketing surveillance.

Frequency-Classified Adverse Reactions

The most frequently reported effects, classified as Very Common (1/10) in regulatory documents, include Headache and Flushing (vasodilation). Effects classified as Common (1/100 to <1/10) include Dyspepsia (indigestion), Nasal congestion, certain forms of Abnormal vision (such as color tinge or blurred vision), Dizziness, and Back pain.

System-Organ Class (SOC) Examples of Officially Listed Adverse Reactions
Nervous System Headache, Dizziness
Vascular Flushing
Eye Disorders Abnormal vision, including color tinge
Gastrointestinal Dyspepsia

Serious Adverse Reactions and Safety Constraints

The regulatory safety profile also includes documentation of rare but clinically significant reactions. These include reports of Priapism (a prolonged erection lasting longer than four hours), Non-arteritic Anterior Ischaemic Optic Neuropathy (NAION) which can cause sudden vision loss, and sudden decrease or loss of hearing. Serious cardiovascular events, such as Myocardial Infarction or Stroke, have also been reported post-marketing in temporal association with use.

Regulatory documents establish absolute restrictions for use, notably prohibiting co-administration with any form of nitrate or nitric oxide donor due to the risk of severe hypotension. Safety constraints also apply to patients with specific underlying conditions, including severe hepatic impairment, severe hypotension ( BP < 90/50 mmHg), a history of certain retinal disorders, or a recent history of stroke or myocardial infarction.

Overdose and Emergency Response

Overdose Scope

Documented Overdose Presentations: Overdose involving Majegra, which contains Sildenafil Citrate, primarily results in an increased rate and severity of adverse events known to occur at therapeutic doses. Clinical manifestations observed in regulatory studies included pronounced decreased blood pressure (hypotension) and syncope (fainting), particularly associated with higher systemic exposures. This exacerbation of effects was observed at single doses up to 800 mg. The occurrence of a prolonged erection is also a documented manifestation in high-exposure scenarios.

Emergency Actions and Help-Seeking: The regulatory profile explicitly states that individuals must seek immediate medical attention for certain severe clinical events. Specifically, patients are instructed to get medical help right away if an erection lasts longer than four hours (priapism), as this condition carries the serious risk of penile tissue damage and permanent loss of potency. Immediate medical assistance is also required in the event of sudden loss of vision. In cases of accidental overdose, individuals should contact a doctor or proceed to the nearest hospital emergency room for assessment.

Management Constraints: Management of overdose is confined to standard supportive measures and symptomatic treatment. Regulatory documents confirm that no specific antidote is known for Sildenafil overdose. Furthermore, due to the active substance's high protein binding, procedures such as haemodialysis are not expected to accelerate clearance.

Therapeutic Uses of Majegra

What Majegra Treats: Main Uses and Benefits

Supporting Functional Blood Flow and Male Sexual Health

Majegra is commonly used to help with Erectile Dysfunction (ED), a condition where symptoms related to physical discomfort interfere with daily functioning by making it difficult to achieve or maintain an erection firm enough for satisfactory sexual performance. The active ingredient is relevant for easing symptoms that create noticeable physiological strain. The overall therapeutic benefit assists with maintaining functional stability and contributes to easing the overall symptom load associated with the condition.

Easing Symptoms of Pulmonary Vascular Restriction

The medication is also applied in conditions characterized by periods of heightened symptoms related to Pulmonary Arterial Hypertension (PAH), a type of high blood pressure affecting the lungs. It is relevant for easing symptoms that interfere with physical endurance, such as limited exercise capacity and shortness of breath. Majegra may be part of symptomatic management, supporting the patient during difficult episodes by helping to improve day-to-day comfort and physical stability.

Quick Fact: Relief for Functional Strain

Majegra is commonly used to help with symptoms that create noticeable functional strain, particularly those linked to insufficient blood flow during sexual arousal or restrictive blood pressure in the lungs.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Who Can and Cannot Use Majegra?

Eligibility for Majegra (Sildenafil Citrate) is determined strictly by regulatory guidelines that define allowed, restricted, and prohibited population groups.

Contraindicated Populations

Use is absolutely prohibited for patients concurrently taking organic nitrates or nitric oxide donors in any form, or Riociguat, due to the risk of severe low blood pressure. The medicine is also contraindicated for individuals with a history of NAION (non-arteritic anterior ischaemic optic neuropathy) or those who have had a stroke or myocardial infarction within the last six months. Patients with severe cardiovascular disorders where sexual activity is deemed inadvisable are ineligible.

Age and Condition Restrictions

Majegra is not indicated for women for the Erectile Dysfunction (ED) use and is contraindicated in individuals under 18 years for the ED indication. While use is established in adults, a reduced starting dose may be necessary for older adults (65 years and over) or those with severe renal or hepatic impairment.

Eligibility Summary

The regulatory framework establishes eligibility primarily for adult men with the approved indications and strictly excludes those with specific cardiovascular risks, nitrate use, or known severe organ function impairment, as detailed in the official prescribing information.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documentation structures the interaction profile of Majegra (Sildenafil) around substances that affect blood pressure and those that modify the drug's plasma exposure.

Contraindicated Combinations

Co-administration with Organic Nitrates (e.g., Nitroglycerin) or Nitric Oxide Donors is formally prohibited due to the risk of severe, sustained hypotensive effects. Likewise, combining Sildenafil with Guanylate Cyclase (GC) Stimulators (e.g., Riociguat) is contraindicated due to additive blood pressure lowering.

Pharmacokinetic and Pharmacodynamic Interactions

Interaction Type Interacting Substance/Class Official Regulatory Outcome
Pharmacokinetic Strong CYP3A4 Inhibitors (e.g., Ritonavir) Increases Sildenafil plasma levels by inhibiting clearance.
Pharmacodynamic Alpha-Blockers (Antihypertensives) Potentiates the hypotensive effect, leading to a risk of symptomatic low blood pressure.
Pharmacodynamic Oral Vitamin K Antagonists Increased incidence of epistaxis (nosebleeds) has been documented in certain populations.

Interaction-Related Restrictions and Notes

The administration of nitrates is restricted, requiring a separation of at least 24 hours post-Sildenafil dosing. In cases of co-administration with strong CYP3A4 inhibitors, a mandatory dose restriction limits the use of Sildenafil over a 48-hour period. Higher Sildenafil plasma concentrations are observed in patients with Severe Hepatic Impairment and in the Elderly (age > 65 years), necessitating a formal restriction on use in severe hepatic cases.

Mechanism of Action

How Majegra Works

Selective Enzyme Inhibition and cGMP Preservation

Majegra's active component, Sildenafil, exerts its fundamental action through the competitive inhibition of the enzyme Phosphodiesterase type 5 (PDE5). This enzyme is highly concentrated in the smooth muscle tissue of the penile corpus cavernosum and vascular beds. By binding to the active site of PDE5, Sildenafil preserves the secondary messenger cyclic Guanosine Monophosphate (cGMP) in smooth muscle cells, resulting in the enhancement of the physiological signal that regulates smooth muscle relaxation.

Amplification of the Nitric Oxide Signaling Cascade

The drug exerts its effect by acting downstream of the naturally occurring Nitric Oxide (NO)-cGMP pathway, only functioning when NO is released following appropriate stimulation. By protecting cGMP from degradation, the drug consequently prolongs the duration and magnitude of the vascular signal, resulting in a prolonged relaxation of the arterial smooth muscle.

Modulation of Local Vascular Hemodynamics

The resulting sustained smooth muscle relaxation causes localized vasodilation, leading to an increased local blood inflow to the target tissue. This hemodynamic modulation is the physiological consequence of the molecular mechanism, leading to the sustained tissue engorgement required for the drug's effect profile.

Dosage and Administration Information

How to Use Majegra: Official Administration Guidelines

Majegra (Sildenafil) is administered via the oral route as a film-coated tablet for its two main approved indications, with distinct dosing and scheduling protocols.

Administration for Erectile Dysfunction (ED)

The medication for ED is used as needed, not to exceed once per day. The usual starting dose is 50 mg, taken approximately one hour prior to anticipated activity, though administration anywhere from 30 minutes to 4 hours beforehand is permitted. The dose may be adjusted from 25 mg up to a maximum of 100 mg based on individual response and toleration. The tablet may be taken with or without food; however, a high-fat meal may lead to a delay in the onset of effect.

Administration for Pulmonary Arterial Hypertension (PAH)

For the PAH indication, the medicine is administered in a scheduled regimen. The standard oral dose is 20 mg, taken three times a day (TID). Doses must be taken approximately 4 to 6 hours apart to maintain consistent systemic levels. This dose may be titrated up to a maximum of 80 mg three times daily depending on tolerability. An intravenous (IV) bolus injection of 10 mg is an approved alternative when patients are temporarily unable to tolerate the oral form.

Population-Specific Dosing

Specific populations may require a reduced starting dose for the ED indication. A starting dose of 25 mg should be considered for older adults, and for patients with severe renal impairment (creatinine clearance less than 30 mL/min) or hepatic impairment (e.g., cirrhosis). No dose adjustment is generally required for renal or mild-to-moderate hepatic impairment when using the PAH dosing regimen.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Majegra

Evidence for use in Erectile Dysfunction

Research examining Sildenafil's use has largely consisted of short-term, placebo-controlled, randomized controlled trials (RCTs). These trial designs are used in research when exploring how symptoms change over time in the observed populations. Researchers was studied for patient experience, primarily using validated questionnaires like the International Index of Erectile Function (IIEF-EF). These tools are designed to measure outcomes reflecting daily functioning or activity level, specifically the reported ability to achieve and sustain an erection sufficient for satisfactory sexual activity.

Research explored how men with Erectile Dysfunction (ED) of various documented causes responded during these defined, short-term study intervals. Studies monitored changes measured during the study period, and findings describe patterns observed in the studies regarding the reported functional ability of participants relative to a placebo control group. The evidence base for this condition contributes to the broader evidence landscape by exploring short-term changes in patient-reported function.

Evidence for use in Pulmonary Arterial Hypertension (PAH)

The evidence supporting the study of Sildenafil in Pulmonary Arterial Hypertension (PAH) also comes from large randomized controlled trials, sometimes comparing different dose tiers. These studies explored outcomes related to systemic or functional imbalance in the lungs, specifically in patients with conditions marked by functional limitations (WHO Functional Class II and III).

Researchers examined functional capacity using the 6-Minute Walk Distance (6MWD), which is a standardized test monitoring physiological strain or stress. Research also monitored for a combined endpoint known as Time to Clinical Worsening, which tracks severe events such as hospitalization or exacerbation. Studies report how symptoms evolved in the observed populations, and the research examined short-term changes in exercise capacity, which is a key measure for this condition.

Long-term Follow-up and Durability of Evidence

For both indications, the most detailed data on how the drug was studied comes from short-term efficacy trials (typically lasting a few weeks or months). While these trials contributed to the initial evidence landscape, researchers recognized the need for longer-duration data. Consequently, research explored longer follow-up in extension studies that tracked patients for up to one year or more, particularly for PAH. However, follow-up durations were limited in many of the initial pivotal trials, meaning long-term effects are not fully established and require continuous monitoring.

Evidence in Specific Patient Populations

Research has also explored certain specific groups. For ED, subgroup analysis was evaluated in men with common concurrent conditions, such as diabetes mellitus or hypertension. For PAH, dedicated research examined outcomes in pediatric patients (children aged 1 to 17 years). These studies monitored functional parameters and disease progression over time.

What is Still Uncertain About the Research

The research provides context but not individual predictions, and evidence highlights what is known—and what is still uncertain. A key limitation is that the results apply only to the populations studied, meaning findings describe group patterns, not personal outcomes. For ED, comparative evidence is lacking against all other active pharmacological treatments. For PAH, the findings were mixed regarding extended-duration study endpoints and dosing patterns, particularly within the pediatric population, and research in this area is still ongoing.

Frequently Asked Questions (FAQ)

Common questions about Majegra (FAQ)

Q: How quickly does Majegra start working after it is taken?

According to official product information, the active ingredient's maximum concentration in the blood is typically reached between 30 and 120 minutes, with a median time of 60 minutes after taking the tablet on an empty stomach. This time frame corresponds to when the body may have absorbed the highest amount of the active ingredient.

Q: How long can the effects of Majegra typically last?

Studies and official information indicate that the effects are generally described as lasting for up to four hours. However, its main action is generally reported to be less prominent after approximately two hours.

Q: Does Majegra work if I am not sexually aroused?

Official documents state that Majegra’s active ingredient only works to prolong the body’s natural response to stimulation. It does not initiate an erection; it requires accompanying sexual stimulation to function.

Q: What are the recommendations regarding alcohol consumption while using Majegra?

The medicine has vasodilatory properties, and combining it with alcohol may lead to an additive effect on blood pressure. This could potentially increase the risk of associated side effects such as dizziness or lightheadedness.

Q: Does Majegra interact with blood thinner medications?

A higher incidence of nosebleeds (epistaxis) was observed in some studies involving patients taking an oral vitamin K antagonist, which is a type of blood thinner. Furthermore, the safety of Majegra is unknown in patients with existing bleeding disorders.

Q: Are there long-term side effects that occur with extended use of Majegra?

Long-term safety was explored in extension studies that tracked patients for up to four years. While continuous monitoring is always required, no lasting adverse effects were reported in the specific populations studied during these extended intervals.

Q: Is Majegra known to be habit-forming?

Official documentation does not classify the medicine’s active ingredient as a controlled substance. It is also not described in regulatory documents as a medicine associated with habit formation or dependence.

Q: Is Majegra used to treat any conditions besides erectile dysfunction?

Yes, Majegra’s active ingredient, Sildenafil, is approved for two distinct medical uses. It is indicated for the treatment of erectile dysfunction (ED) and also for the treatment of pulmonary arterial hypertension (PAH).

Q: Can Majegra interact with common over-the-counter pain relievers?

The official regulatory interaction documentation does not list any specific common over-the-counter pain relievers, such as acetaminophen or NSAIDs, as being contraindicated or having a known major interaction with Majegra's active ingredient.

Q: Are there any known interactions between Majegra and grapefruit juice?

Studies indicate that grapefruit juice may increase the amount of the active ingredient in the body and may delay the time it takes for the medicine to begin working. Official guidance indicates that the regular consumption of large amounts of grapefruit juice should be limited.

Q: Is Majegra considered a permanent cure for erectile dysfunction?

The medicine is described as a treatment for symptoms of erectile dysfunction, not a permanent cure for the underlying condition. Its purpose is to assist the body’s natural response when stimulation occurs.

Q: What research evidence supports the use of Majegra for its stated purpose?

Support for its use comes primarily from short-term, randomized, controlled clinical trials (RCTs). These studies monitored patient-reported outcomes, such as the ability to achieve and maintain an erection, and for PAH, they measured changes in functional capacity like the 6-Minute Walk Distance (6MWD).

Q: Is Majegra an approved treatment in major countries like the US or Europe?

Yes, the active ingredient in Majegra is an approved prescription medicine. It has been granted marketing authorization by major regulatory bodies globally, including the United States Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

Q: What is the difference in how Majegra is used for ED versus pulmonary hypertension?

The two indications have different administration protocols. For erectile dysfunction (ED), it is used as needed up to once per day. For pulmonary arterial hypertension (PAH), it is taken on a scheduled basis, typically three times per day, using different dose strengths.

Q: Is Majegra approved for use in patients with high blood pressure (hypertension)?

The active ingredient has been explored in men with concurrent conditions, including hypertension. However, because Majegra has vasodilatory properties, caution is generally advised and patients taking other blood pressure-lowering drugs may require careful monitoring.

Q: Can Majegra cause ringing in the ears (tinnitus)?

The rare but serious adverse event of sudden decrease or loss of hearing has been reported post-marketing. This hearing change may occasionally be accompanied by other symptoms, such as ringing in the ears (tinnitus).

Q: Is Majegra a branded or generic version of its active ingredient?

Majegra is a specific commercial identifier for a product containing the active ingredient Sildenafil Citrate. The product is identified in official documents as a film-coated tablet containing the single active component Sildenafil.

Q: Can Majegra be taken on an empty stomach?

The official administration guidelines explicitly state that the tablet may be taken with or without food. However, taking it with a heavy or high-fat meal may lead to a delay in the onset of its effect.

Q: Is it true that Majegra's effect is less after two hours?

Yes, official documents indicate that while the medicine remains in the body and continues to work for up to four hours, its main action is generally reported to be less prominent after the two-hour mark.

Q: What are the official warnings about using Majegra if one has a curved penis or other abnormality?

Caution is advised when the medicine is used in patients who have a physical abnormality of the penis, such as curving (Peyronie's disease) or birth defects. This caution is related to the potential for an increased risk of a prolonged erection (priapism).

Q: Does Majegra offer any protection against sexually transmitted infections (STIs)?

The official patient counseling information explicitly states that Majegra's active ingredient offers no protection against sexually transmitted infections (STIs), including the human immunodeficiency virus (HIV).

How should Majegra be stored and disposed of?

Official Storage and Handling Requirements

Majegra (Sildenafil) tablets must be stored at Controlled Room Temperature, as defined by regulatory standards, to maintain product stability and integrity.

Item Requirement
Temperature Range Store between 20 C and 25 C (68 F and 77 F). Permitted excursions extend from 15 C to 30 C (59 F and 86 F).
Environmental Protection Keep the medication in the original container to protect it from moisture, and keep the container tightly closed.
Child Safety The medication must be kept out of the sight and reach of children.

Disposal Instructions

Any unused or expired Majegra must be discarded in accordance with local regulatory requirements for pharmaceutical waste. Disposal should follow established programs, such as authorized drug take-back sites, and generally should not involve throwing the medicine into the household trash or flushing it down a toilet, unless a governing authority explicitly advises otherwise.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Majegra found in:

A-Z Index: